(Q38452930)

3 September 2017

title

Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x (English)

1 reference

adaptive radiation therapy

3 September 2017

main subject

0 references

1 reference

Andrew C. von Eschenbach

5

object named as

Andrew C von Eschenbach

1 reference

3 September 2017

Alan Pollack

1

1 reference

3 September 2017

Didier Cowen

2

1 reference

3 September 2017

Patricia Troncoso

3

1 reference

3 September 2017

Gunar K Zagars

4

1 reference

3 September 2017

Marvin L Meistrich

6

1 reference

3 September 2017

Timothy McDonnell

7

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

3 September 2017

1 reference

3 September 2017

volume

97

1 reference

3 September 2017

issue

7

1 reference

3 September 2017

page(s)

1630-1638

1 reference

Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Effect of Bcl-2 overexpression in human prostate cancer cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Bcl-XL and Bcl-2 repress a common pathway of cell death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Multiple Bcl-2 family members demonstrate selective dimerizations with Bax

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Prostate tumours from an Asian population: examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Intestinal cell radiosensitivity: a comparison for cell death assayed by apoptosis or by a loss of clonogenicity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Lack of prostate cancer radiosensitization by androgen deprivation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Bcl-2 accelerates multistep prostate carcinogenesis in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11230

7 January 2021

Identifiers

DOI

10.1002/CNCR.11230

1 reference

3 September 2017

1 reference